Calamos Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$284M Buy
308,497
+35,943
+13% +$36.4M 1.01% 15
2025
Q4
$293M Sell
272,554
-1,759
-0.6% -$1.68M 1.1% 14
2025
Q3
$209M Sell
274,313
-4,255
-2% -$3.17M 0.77% 20
2025
Q2
$217M Buy
278,568
+5,462
+2% +$4.24M 0.85% 15
2025
Q1
$226M Sell
273,106
-18,870
-6% -$15.7M 0.98% 14
2024
Q4
$225M Buy
291,976
+3,433
+1% +$2.84M 0.94% 14
2024
Q3
$256M Sell
288,543
-42,859
-13% -$38.5M 1.11% 10
2024
Q2
$300M Sell
331,402
-6,332
-2% -$5.07M 1.33% 11
2024
Q1
$263M Sell
337,734
-36,110
-10% -$25.7M 1.24% 8
2023
Q4
$218M Sell
373,844
-2,892
-0.8% -$1.69M 1.06% 9
2023
Q3
$202M Sell
376,736
-10,119
-3% -$5.21M 1.05% 11
2023
Q2
$181M Sell
386,855
-28,107
-7% -$11.8M 0.9% 12
2023
Q1
$143M Sell
414,962
-33,993
-8% -$11.5M 0.7% 15
2022
Q4
$164M Sell
448,955
-53,957
-11% -$19.1M 0.77% 12
2022
Q3
$163M Buy
502,912
+6,388
+1% +$2.02M 0.74% 14
2022
Q2
$161M Sell
496,524
-3,941
-0.8% -$1.18M 0.69% 15
2022
Q1
$143M Buy
500,465
+14,078
+3% +$3.62M 0.54% 22
2021
Q4
$134M Buy
486,387
+28,041
+6% +$7.11M 0.5% 26
2021
Q3
$106M Sell
458,346
-7,972
-2% -$1.97M 0.46% 33
2021
Q2
$107M Buy
466,318
+67,739
+17% +$13.6M 0.49% 33
2021
Q1
$74.5M Buy
398,579
+56,221
+16% +$11M 0.41% 46
2020
Q4
$57.8M Sell
342,358
-17,617
-5% -$2.63M 0.34% 67
2020
Q3
$53.3M Buy
359,975
+18,125
+5% +$2.81M 0.34% 65
2020
Q2
$56.1M Buy
341,850
+88,227
+35% +$13.5M 0.4% 57
2020
Q1
$35.2M Sell
253,623
-11,751
-4% -$1.61M 0.28% 107
2019
Q4
$34.9M Sell
265,374
-2,577
-1% -$299K 0.17% 163
2019
Q3
$30M Sell
267,951
-13,782
-5% -$1.53M 0.16% 176
2019
Q2
$31.2M Buy
281,733
+5,856
+2% +$690K 0.17% 174
2019
Q1
$35.8M Buy
275,877
+112
+0% +$13.6K 0.22% 147
2018
Q4
$31.9M Buy
275,765
+20,341
+8% +$2.27M 0.21% 135
2018
Q3
$27.4M Buy
255,424
+6,841
+3% +$684K 0.15% 177
2018
Q2
$21.2M Buy
248,583
+13,311
+6% +$1.09M 0.13% 210
2018
Q1
$18.2M Buy
235,272
+4,729
+2% +$381K 0.12% 229
2017
Q4
$19.5M Sell
230,543
-167,586
-42% -$14.3M 0.1% 206
2017
Q3
$34.1M Buy
398,129
+1,998
+0.5% +$164K 0.26% 116
2017
Q2
$32.6M Buy
396,131
+6,879
+2% +$561K 0.24% 121
2017
Q1
$32.7M Sell
389,252
-206
-0.1% -$16.5K 0.26% 110
2016
Q4
$28.6M Sell
389,458
-43,461
-10% -$3.24M 0.23% 133
2016
Q3
$34.7M Buy
432,919
+97
+0% +$7.76K 0.25% 130
2016
Q2
$34.1M Buy
432,822
+37
+0% +$2.79K 0.24% 136
2016
Q1
$31.2M Buy
432,785
+6,148
+1% +$465K 0.21% 154
2015
Q4
$35.9M Hold
426,637
0.23% 133
2015
Q3
$35.7M Buy
426,637
+32
+0% +$2.7K 0.25% 129
2015
Q2
$35.6M Sell
426,605
-14,109
-3% -$1.08M 0.22% 141
2015
Q1
$32M Buy
440,714
+8,958
+2% +$638K 0.2% 148
2014
Q4
$29.8M Buy
431,756
+506
+0.1% +$34.2K 0.2% 139
2014
Q3
$28M Hold
431,250
0.19% 141
2014
Q2
$26.8M Buy
431,250
+7,000
+2% +$418K 0.17% 153
2014
Q1
$25M Hold
424,250
0.16% 166
2013
Q4
$21.6M Hold
424,250
0.14% 177
2013
Q3
$21.4M Buy
424,250
+90,000
+27% +$4.71M 0.13% 168
2013
Q2
$16.4M Buy
+334,250
New +$18.2M 0.11% 190

Other funds holding LLY

Calamos Advisors's LLY Position: Q1 2026 in Review

Calamos Advisors increased its Eli Lilly (LLY) stake by 13% in Q1 2026, buying an estimated $36.4M and bringing the position to 308,497 shares worth $284M. The position accounts for 1.01% of the portfolio, ranked #15.

Calamos Advisors first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $300M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Calamos Advisors held 308,497 shares of Eli Lilly worth $284M as of Q1 2026.
  • Calamos Advisors bought 35,943 Eli Lilly shares in Q1 2026, an estimated $36.4M.
  • Eli Lilly made up 1.01% of Calamos Advisors's portfolio in Q1 2026, its #15 holding.
  • Calamos Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Eli Lilly position peaked at $300M in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.